









**Supplementary Figure 1**



# Supplementary Figure 2


A.



**Supplementary Figure 3**

**A.**

**Chemotherapy regimens in TMA**




**B.**

<u>Overall Survival</u>	Figure refer.	nuclear YAP	1-yr Surv. Rate (95% CI)	3-yr Surv. Rate (95% CI)	Median Surv. (95% CI)	log-rank p-value
All patients	7C	High	0.67 (0.55, 0.77)	0.27 (0.17, 0.38)	19.1 (15.3, 24.5)	< 0.001
		Low	0.86 (0.78, 0.92)	0.59 (0.48, 0.68)	47.8 (35.3, 103.1)	
Chemotherapy patients	7E	High	0.83 (0.51, 0.96)	0.15 (0.02, 0.39)	19.6 (15.3, 24.5)	0.003
		Low	0.83 (0.63, 0.92)	0.51 (0.32, 0.68)	37.8 (27.4, 89.7)	


<u>Recurrence Free Survival</u>	Figure refer.	nuclear YAP	1-yr RFS Rate (95% CI)	3-yr RFS Rate (95% CI)	Median RFS (95% CI)	log-rank p-value
All patients	7D	High	0.52 (0.37, 0.66)	0.22 (0.11, 0.35)	12.9 (7.2, 20.6)	< 0.001
		Low	0.79 (0.68, 0.86)	0.43 (0.32, 0.54)	28.8 (19.0, 55.7)	
Chemotherapy patients	7F	High	0.63 (0.23, 0.86)	0.00 (0.01, 0.42)	12.6 (5.4, 20.1)	0.021
		Low	0.73 (0.49, 0.87)	0.32 (0.14, 0.51)	23.8 (11.5, 55.7)	

# Supplementary Figure 4


A.




B.




C.



D.




E.



# Supplementary Figure 5


**A.**

## Cross-cancer alteration summary for Hippo pathway genes (25 TCGA provisional studies) (YAP1, TAZ, LATS1, LATS2, SAV1, MST1, STK3, NF2)




**B.**

## Cross-cancer alteration summary for YAP1 (25 TCGA provisional studies)



# Supplementary Figure 6

**A.**



**B.**

